Dr. Guangyu Liu 柳光宇
Chief Physician
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of malignant breast tumors, early diagnosis of breast cancer, and multidisciplinary comprehensive therapy.
Dr. Liu is Chief Physician and Deputy Director of the Breast Surgery Department at Fudan University Shanghai Cancer Center. Dr. Liu earned a clinical master’s degree in 2000 and a PhD in clinical oncology in 2004 from Fudan University. Dr. Liu conducted academic exchanges as a visiting scholar at M.D. Anderson Cancer Center (2006–2007) and the University of Manitoba (2002–2003).
Professional roles
- Standing Committee Member, 9th Breast Cancer Professional Committee, China Anti-Cancer Association
- Council Member, 9th Council, Shanghai Anti-Cancer Association
- Former Chair, Breast Cancer Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Liu Guangyu). Papers usually list the name as Guangyu Liu or Liu G.
Selected publications
116 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Br J Cancer, 2026 (senior author): On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort. PubMed 42661023
- Cell Death Dis, 2026 (senior author): Bisphosphate nucleotidase 1 promotes progression and docetaxel resistance in triple-negative breast cancer via STUB1-mediated destabilization of LIMA1. PubMed 41540000
- Med, 2025 (senior author): DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer. PubMed 39520982
- Mol Med Rep, 2024 (senior author): [Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition in vivo. PubMed 39392038
- Breast, 2023 (senior author): Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. PubMed 37839139
- Breast, 2023 (senior author): Prognostic factors and clinical outcomes of breast cancer patients with disease progression during neoadjuvant systemic therapy. PubMed 37352573
- Int J Surg, 2023 (senior author): Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study. PubMed 37132193
- Br J Cancer, 2023 (senior author): Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. PubMed 36717677
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion